Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

HUTCHMED DRC

HCM
Current price
14.61 USD -1.13 USD (-7.18%)
Last closed 15.20 USD
ISIN US44842L1035
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 2 691 177 728 USD
Yield for 12 month -22.74 %
1Y
3Y
5Y
10Y
15Y
HCM
21.11.2021 - 28.11.2021

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong. Address: Cheung Kong Center, Hong Kong, Hong Kong

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

26.36 USD

P/E ratio

78.70

Dividend Yield

Current Year

+630 201 000 USD

Last Year

+837 999 000 USD

Current Quarter

+162 260 000 USD

Last Quarter

+162 260 000 USD

Current Year

+281 317 000 USD

Last Year

+453 552 000 USD

Current Quarter

-28 169 000 USD

Last Quarter

-28 169 000 USD

Key Figures HCM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -31 364 000 USD
Operating Margin TTM -4.99 %
Price to Earnings 78.70
Return On Assets TTM -2.14 %
PEG Ratio
Return On Equity TTM 5.04 %
Wall Street Target Price 26.36 USD
Revenue TTM 630 201 024 USD
Book Value 0.89 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 6.40 %
Dividend Yield
Gross Profit TTM 69 208 000 USD
Earnings per share 0.20 USD
Diluted Eps TTM 0.20 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY -84.20 %
Profit Margin 5.99 %

Dividend Analytics HCM

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History HCM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:1
Payout Ratio TTM
Last Split Date 30.05.2019

Stock Valuation HCM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 78.70
Forward PE 51.55
Enterprise Value Revenue 2.99
Price Sales TTM 4.27
Enterprise Value EBITDA 133.70
Price Book MRQ 3.54

Financials HCM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators HCM

For 52 weeks

11.51 USD 21.92 USD
50 Day MA 14.97 USD
Shares Short Prior Month 357 656
200 Day MA 16.71 USD
Short Ratio 4.30
Shares Short 360 596
Short Percent 0.35 %